Drugs / 18F-ISO-1
18F-ISO-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02284919 | Mar 2015 → Nov 2026 expected | breast cancer | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00968656 | Jan 2009 → Nov 2011 | breast cancer, diffuse large B-cell lymphoma, head and neck cancer | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-ISO-1 | “The feasibility of using N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumors in lymphoma,...” PMID 31836680 ↗ Dec 2019 |
| Known as | F-18-ISO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968656 ↗ |
| Known as | N-(4-(6,7-dimethoxy-3,-4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[18F]-fluoroethoxy)-5- Methylbenzamide ([18F]ISO-1) | “N-(4-(6,7-dimethoxy-3,-4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[18F]-fluoroethoxy)-5- Methylbenzamide ([18F]ISO-1)” NCT02284919 ↗ |
| Known as | N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide | “The feasibility of using N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumors in lymphoma,...” PMID 31836680 ↗ Dec 2019 |
| Modality | Diagnostic / imaging agent | “a radioactive tracer called 18F-ISO-1” NCT00968656 ↗ |
| Route | Intravenous | “Patients receive F-18-ISO-1 i.v.” NCT00968656 ↗ |